Part:BBa_K5302002:Experience

This experience page is provided so that any user may enter their experience using this part.
Please enter how you used this part and how it worked out.

Applications of BBa_K5302002

This year, the USTC iGEM team has utilized the competitive binding of vascular endothelial growth factor (VEGF) to develop a targeted bacterial therapy for solid tumors. Our quest for the optimal VEGF-binding protein(or peptide) led us to an in-depth exploration of proteins structurally akin to the vascular endothelial growth factor receptor (VEGFR), which we have named VEGFR-like. 8IIU is an anti-VEGF nanobody, and it has 2 chains.These two chains all show great affinity with VEGF, we used pBBR1MCS-2 plasmid as a backbone and transfered 8IJZ into Escherichia coli Nissle 1917,and finally succeeded in expressing 8IJZ.

[1]Zhu S, Fan S, Tang T, Huang J, Zhou H, Huang C, Chen Y, Qian F. Polymorphic nanobody crystals as long-acting intravitreal therapy for wet age-related macular degeneration. Bioeng Transl Med. 2023 May 4;8(6):e10523. doi: 10.1002/btm2.10523. PMID: 38023710; PMCID: PMC10658565.

User Reviews

UNIQ534f817bc69dd531-partinfo-00000000-QINU UNIQ534f817bc69dd531-partinfo-00000001-QINU